[
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Study selection and data extraction\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Of these, 23 guidelines were identified for further review (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "One was developed by WHO, and four in Europe (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Quality assessment\nThe included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The included 23 guidelines were appraised using AGREE II Criteria (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The screening recommendations for women at average risk\nThe detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Preventive Services Task Force; WHO: World Health Organization.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The detailed information of recommendations for average-risk women is shown in Table 3, which summarized screening age, screening methods, screening intervals, and other recommended screening methods (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "MAM: annual\n\n\nKnown genetic predisposition of breast cancer\nACR, 2017 [19]\nNR\n\n\n■MAM or DBT is recommended;\n\n\n■MRI may be considered as an adjunct to MAM or DBT;\n\n\n■US is recommended when the patient cannot tolerate MRI\n\n\n\n\nACR (High-risk), 2017 [20]\n30 years\nDM+/DBT: annual\n\n\n25–30 years\nMRI: annual\n\n\nACR and SBI, 2010 [22]\nStart by age 30 but not before age 25\nMAM: annual\n\n\nEUSOMA, 2010 [26]\nStart from 30 years;Before 30 years [discuss, mutation carrier of BRCA1 or BRCA2 (start from 25 to 29) and TP53 (start from 20)]\nMRI: annual\n\n\nMOH of Singapore, 2010 [30]\nStart at age 25–30 years for BRCA mutation carriers and their untested first-degree relatives, or as early as 5–10 years before the age of onset of breast cancer in the youngest family member in those with family history of breast cancer but no proven mutation\n\n\n■BSE: monthly [Grade D];\n\n\n■CBE: 6 monthly [Grade D];\n\n\n■MAM and MRI: annual [Grade D]\n\n\n\n\nMOH of Malaysia, 2019 [31]\n30–49 years\nMRI: annual\n\n\n40–69 years\nMAM: annual\n\n\n≥70 years\nMAM: biennial\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nFrom 30 years\nMAM annual [category B recommendation]\n\n\nFrom 25 years\nMRI annual [category A recommendation]\n\n\nHistory of mantle or chest radiation therapy\nNCCN, 2019 [18]\nStart from 10 years after radiation exposure\nBreast awareness and clinical encounter: every 6–12 months\n\n\nStart from 10 years after radiation exposure but not less than age 30\nDM: annual, with consideration of tomosynthesis\n\n\nStart from 10 years after radiation exposure but not less than age 25\nMRI: annual\n\n\nStart from 10 years after radiation exposure for women younger than 25 years who have received prior thoracic irradiation\nBreast awareness, counseling on risk and an annual clinical encounter\n\n\nACR, 2017 [19]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nMAM\n\n\nACR (High-risk), 2017 [20]\nStart from age 25 or 8 years after radiation therapy, whichever is later\nDM+/DBT: annual\n\n\nNCC China, 2020 [32]\nNR\nMRI: annual\n\n\nCEWG, 2018 [33]\nBegin at age 35\n\n\n■MAM: annual;\n\n\n■Consider MAM + MRI: annual\n\n\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nStart from the 8th year after radiotherapy onward, but not begin before age 30\nMAM: annual [category C recommendation]\n\n\nStart from the 8th year after radiotherapy onward, but not begin before age 25\nMRI: annual [category C recommendation]\n\n\nDense breasts\nACR, 2017 [19]\nNR\nConsider: US\n\n\nACR (High-risk), 2017 [20]\nNR\n\n\n■MRI: annual;\n\n\n■The addition of US to MAM may be useful\n\n\n\n\nACR and SBI, 2010 [22]\nNR\nConsider: US as an adjunct to MAM\n\n\nChina NCC, 2020 [32]\nNR\nMAM and US: annual\n\n\nCBR, SBM, and FEBRASGO, 2017 [35]\nNR\nConsider: US as an adjunct to MAM\n\n\n\nOpen in a new tab\nAbbreviations: ACR: American College of Radiology; BRCA: Breast cancer gene; BSE: Breast Self-Examination; CBE: Clinical Breast Examination; CBR: Brazilian College of Radiology and Diagnostic Imaging; CEWG: Cancer Expert Working Group; DBT: Digital Breast Tomosynthesis; DM: Digital Mammography; ESMO: European Society for Medical Oncology; EUSOMA: European Society of Breast Cancer Specialists; FEBRASGO: Brazilian Federation of Gynecological and Obstetrical Associations; MAM: mammography; MOH: Ministry of Health; MRI: Magnetic Resonance Imaging; NCC: National Cancer Centre; NCCN: National Comprehensive Cancer Network; NR: No Recommendation; SBI: Society of Breast Imaging; SBM: Brazilian Society for Breast Disease; US: Ultrasound.Fig. 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For women at higher risk, there was a consensus among most guidelines that annual MAM screening or annual MRI screening should be given and the starting age should be earlier than the average-risk group (Table 4; Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  }
]